HEK293 Cell Lines for AAV Production via Gene Knockout
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
AAV-mediated gene therapy faces challenges in scaling AAV vector production for commercial use, as current methods are inefficient and difficult to scale up.
Innovation Solution
Genetically engineered HEK293 cell lines are developed with reduced expression of specific genes such as TMED10, MON2, and HS2ST1, and increased expression of genes like B4GALT7, using CRISPR genome editing and RNA interference to enhance AAV production capacity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If traditional triple transfection of HEK 293 cells is used to produce AAV vectors, then the production process is simple to implement, but the AAV production capacity is insufficient for commercial scaling
Solution Approach 1:
The patent modifies cellular parameters by knocking out specific genes (TMED10, MON2, TMED2, HS2ST1, C3orf58, SPPL3, SURF4, LSM5, ARF1, PI4KB) to change the cellular environment for improved AAV production. This genetic parameter modification enables higher AAV yields while maintaining process simplicity
Solution Approach 2:
The patent extracts and removes specific genes from the HEK 293 cell line that hinder AAV production. By taking out these problematic genes through CRISPR/Cas9 editing, the cell line is optimized for commercial-scale AAV manufacturing without adding complex production steps
2Productivity
If gene expression is modified to improve AAV production, then AAV vector yield increases, but the risk of off-target effects and reduced cell line stability increases
Solution Approach 1:
The patent implements rigorous validation and characterization of the engineered cell lines to ensure stability. Through multiple rounds of testing and verification of AAV production consistency, the patent confirms that the modified cell lines maintain reliability while achieving improved yields
Solution Approach 2:
The patent creates stable cell lines with defined genetic modifications that can be used for multiple production batches. By establishing robust, character化的 cell lines, the invention avoids the need for repeated transfections and maintains consistent performance over time
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified cell lines significantly increase AAV vector production, allowing for more efficient and scalable production of AAV particles, which can be used in pharmaceutical compositions for treating diseases.
Implementation Method 1
The expression of at least one of TMED10, MON2, TMED2, HS2ST1, C3orf58, SPPL3, SURF4, LSM5, ARF1, and PI4 KB may be reduced using CRISPR genome editing
Implementation Method 2
The expression of at least one of TMED10, MON2, TMED2, HS2ST1, C3orf58, SPPL3, SURF4, LSM5, ARF1, and PI4 KB may be reduced using CRISPR genome editing, a double stranded RNA (dsRNA), a small interfering RNA (siRNA), a small hairpin RNA (shRNA), a micro RNA or an antisense RNA
Data Source
AI summary
Provided herein are systems for increasing AAV particle production. These systems comprise producer cell lines adapted for the production of AAV particles, as well as methods of producing AAV particles using said producer cell lines. Also provided are AAV particles produced by said production systems, producer cell lines and methods.